Q4 largely in line, Q1 likely flat Contracts developing slowly - lower target range likely Weak '24 ...
Redeye comments on Cantargia's Q4 report. The company faces a major catalyst in the first placebo-co...
Redeye comments on the outcome of Freemelt’s rights issue.
'25e-'26e EBIT up 6-15% Return to organic growth likely in Q2'25 '25e-'26e EV/EBIT of 14x-6x Starti...
Redeye provides an updated view on Xbrane following its year-end report, which showed continued grow...
Redeye saw a report with sales that were lower than our expectations.
Redeye provides an update following CLS’s Q4 2024 report.
Q4 net sales and clean EBIT were broadly in line with consensus.
Q4 NAV beat our estimate... ...driven by valuation increases in private portfolio Fair value increas...
Absolent’s Q4 numbers are well in line with Redeye’s expectations on Group level in terms of sales a...
Luxbright har publicerat Bolagets bokslutskommuniké för år 2024.
Sales -4% vs. ABGSCe (-11% y-o-y), EBIT -24% vs. ABGSCe Weaker orders but improving margins, partly ...
Today, 13.00-13.45, Clinical Laserthermia Systems CEO Dan Mogren and CFO Håkan Rosqvist will present...
Analyst Group inleder idag den 21:e februari 2024 analysbevakning på Cedergrenska AB (”Cedergrenska”...
Sales SEK 432m +3% vs. ABGSCe 419m EBIT better than expected Consensus EBIT estimate revisions likel...
